Acrivon Therapeutics
ACRV | NASDAQ
$1.46
+$0.01 (+0.69%)
At close: Nov 16, 2026, 4:00 PM ET
$1.43
-$0.03 (-1.84%)
After-hours:
Nov 16, 2026, 7:30 PM ET
+0.69%
(1D)No price chart data available for 1D timeframe.
Rating
32.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #738/1021 (Top 72%)
Key Statistics
Market Data
Market Cap $62.57M
1D Range
1.40 1.49
52W Range
1.29 3.01
Valuation (TTM)
PE -0.78
PB 0.72
EV/EBITDA 0.32
Valuation (NTM)
Forward PE N/A
Forward PEG 0.09
Price Target $20.00
Cash Flow
FCF Yield -102.5%
SBC Adj. FCF Yield -120.7%
SBC Impact -17.8%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 19.4% |
-11.5%
FCF 3Y | 5Y -6.9% |
-30.9%
Returns
ROA -74.9%
ROE -70.1%
ROIC -88.3%
Financial Health
Net Cash
$87.84M
Current Ratio 7.99
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumor...
Sector Healthcare
Industry Biotechnology
Employees 75
IPO Date Nov 15, 2022
Website www.acrivon.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$20.00
Upside
+1269.86%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ACRV